达雷妥尤单抗、环磷酰胺、硼替佐米、来那度胺和地塞米松作为诱导和延长巩固治疗改善超高危多发性骨髓瘤的结局
多中心II期OPTIMUM(MUKnine)试验在分子定义超高危(UHiR)新诊断多发性骨髓瘤(NDMM)或浆细胞白血病(PCL)患者中,评估达雷妥尤单抗、低剂量环磷酰胺、来那度胺、硼替佐米和地塞米松(Dara-CVRd)在自体干细胞移植(ASCT)前后的疗效。主要结果显示,30个月随访时OPTIMUM组无进展生存(PFS)为77%,而MyeXI外部对照组为39.8%;总生存(OS)分别为83.5%和73.5%。作者认为该策略显著改善UHiR NDMM患者的PFS,支持进一步评估。
要点
- OPTIMUM试验中,103例UHiR或PCL患者接受Dara-CVRd诱导、V增强ASCT、延长Dara-VR(d)巩固和Dara-R维持治疗。
- 30个月随访时,OPTIMUM组PFS为77%,MyeXI外部对照组为39.8%;OS分别为83.5%和73.5%。
- 贝叶斯框架比较18个月PFS(PFS18m)显示OPTIMUM优于MyeXI的概率为99.5%。
核心结论
- 作者认为,Dara-CVRd诱导和ASCT后延长Dara-VRd巩固治疗相比传统管理可显著改善UHiR NDMM患者的PFS,支持进一步评估该策略。
研究设计与样本
- 多中心OPTIMUM(MUKnine)II期试验,对适合移植的NDMM患者进行UHiR profiling,UHiR定义为存在≥2个遗传风险标志物t(4;14)/t(14;16)/t(14;20)、del(1p)、gain(1q)和del(17p),和/或SKY92基因表达风险特征。
- 412例筛查的NDMM患者中,103例被确定为UHiR或PCL并接受Dara-CVRd治疗;117例MyeXI患者被确定为UHiR并形成外部对照臂,其临床和分子特征与OPTIMUM可比。
- OPTIMUM组接受Dara-CVRd诱导、V增强ASCT、延长Dara-VR(d)巩固和Dara-R维持治疗;MyeXI组接受卡非佐米、来那度胺、地塞米松和环磷酰胺,或来那度胺、地塞米松和环磷酰胺,ASCT,以及来那度胺维持或观察。
主要发现
- 贝叶斯框架比较PFS18m显示OPTIMUM优于MyeXI的概率为99.5%。
- 30个月随访时,OPTIMUM组PFS为77%,MyeXI组为39.8%;OPTIMUM组OS为83.5%,MyeXI组为73.5%。
- ASCT后延长Dara-VRd巩固治疗可行性高,毒性有限。
关键数值与推荐
- UHiR定义为存在≥2个遗传风险标志物t(4;14)/t(14;16)/t(14;20)、del(1p)、gain(1q)和del(17p),和/或SKY92基因表达风险特征。
- 30个月随访时,OPTIMUM组PFS为77%,MyeXI组为39.8%;OPTIMUM组OS为83.5%,MyeXI组为73.5%。
- 贝叶斯框架比较PFS18m显示OPTIMUM优于MyeXI的概率为99.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) before and after autologous stem-cell transplant (ASCT) in newly diagnosed patients with molecularly defined ultra-high-risk (UHiR) multiple myeloma (NDMM) or plasma cell leukemia (PCL). To provide clinical context, progression-free survival (PFS) and overall survival (OS) were referenced to contemporaneous outcomes seen in patients with UHiR NDMM treated in the recent Myeloma XI (MyeXI) trial. METHODS: Transplant-eligible all-comers NDMM patients were profiled for UHiR disease, defined by presence of ≥2 genetic risk markers t(4;14)/t(14;16)/t(14;20), del(1p), gain(1q), and del(17p), and/or SKY92 gene expression risk signature. Patients with UHiR MM/PCL were offered treatment with Dara-CVRd induction, V-augmented ASCT, extended Dara-VR(d) consolidation, and Dara-R maintenance. UHiR patients treated in MyeXI with carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide, or lenalidomide, dexamethasone, and cyclophosphamide, ASCT, and R maintenance or observation were identified by mirrored molecular screening. OPTIMUM PFS at 18 months (PFS18m) was compared against MyeXI using a Bayesian framework, and patients were followed up to the end of consolidation for PFS and OS. RESULTS: Of 412 screened NDMM OPTIMUM patients, 103 were identified as UHiR or PCL and subsequently treated on trial with Dara-CVRd; 117 MyeXI patients identified as UHiR formed the external comparator arm, with comparable clinical and molecular characteristics to OPTIMUM. Comparison of PFS18m per Bayesian framework resulted in a 99.5% chance of OPTIMUM being superior to MyeXI. At 30 months' follow-up, PFS was 77% for OPTIMUM versus 39.8% for MyeXI, and OS 83.5% versus 73.5%, respectively. Extended post-ASCT Dara-VRd consolidation therapy was highly deliverable, with limited toxicity. CONCLUSION: Our results suggest that Dara-CVRd induction and extended post-ASCT Dara-VRd consolidation markedly improve PFS for UHiR NDMM patients over conventional management, supporting further evaluation of this strategy.
引用
- Kaiser MF, Hall A, Walker K, et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. J Clin Oncol. 2023. PMID: 37315268. doi:10.1200/JCO.22.02567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。